← All trials
NCT02172040
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2014
- Primary completion
- Nov 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 152
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Purple BiotechLead sponsor
- CelerionOverall official - principal investigator
- Rowden SurgeryOverall official - principal investigator
- Aspect ClinicalOverall official - principal investigator
- Medicines Evaluation Unit LtdOverall official - principal investigator
- SynexusOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Purple BiotechStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.